Clinical trials: Dementia of Alzheimer Type
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose.
- Trial name
- NCT00428090
- Testing
- Rosiglitazone
- Where
- 138 sites in United States, Austria and 18 more
- Volunteers
- 862 people
- Sponsor
- GlaxoSmithKline
Dementia of Alzheimer Type
Donepezil Treatment of Psychotic Symptoms in Dementia Patients
Conventional psychotropic medications may be used to treat behavioral disturbances and psychotic symptoms in patients with dementia and they are the drugs of choice for treating delusions and hallucinations.
- Trial name
- NCT00190021
- Testing
- donepezil
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Beersheva Mental Health Center
Alzheimer Disease
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
- Trial name
- NCT00036114
- Testing
- aripiprazole
- Where
- 41 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease, Alzheimer Disease 1
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Alzheimer's disease.
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT04100889
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Mild Cognitive Impairment, Dementia of Alzheimer Type
Stimulation to Improve Memory
This study will test the effects of different doses of a form of non-invasive brain stimulation for the treatment of individuals with mild cognitive impairment (MCI) and dementia of the Alzheimer's Type (DAT).
- Trial name
- STIM (NCT03875326)
- Testing
- 1 mA HD-tDCS, 2 mA HD-tDCS, 3 mA HD-tDCS
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- University of Michigan
Alzheimer Disease
The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients affects their activities of daily living…
- Trial name
- NCT00216515
- Testing
- galantamine hydrobromide
- Volunteers
- 102 people
- Sponsor
- Janssen Korea, Ltd., Korea
Dementia, Alzheimer Type
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors.
- Trial name
- NCT00505167
- Testing
- Memantine, Donepezil
- Where
- 3 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Miguel Servet
Dementia of Alzheimer Type, Dementia Frontotemporal
Multifactorial Approach to Dementia, Multicentric Study
The goal of this observational study is to assess the role of narcisistic personality disorder and life stressful events in conversion rate to dementia, using a three tier approach along three research lines employing subjects…
- Conditions
- Dementia of Alzheimer Type, Dementia Frontotemporal, Narcissistic Personality Disorder, Depression
- Trial name
- NCT05923307
- Where
- Argentina
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Daniel Serrani Azcurra
Alzheimer's Disease
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of…
- Trial name
- MissionAD1 (NCT02956486)
- Testing
- Elenbecestat
- Where
- 258 sites in United States, Argentina and 16 more
- Volunteers
- 2,212 people
- Sponsor
- Eisai Co., Ltd.
Coronary Artery Disease, Diabetes Mellitus, Type 2
PIPAF Platelets in the Pathogenesis of Ageing Associated Frailty
This is a prospective observational study aimed at testing the existence of an association between frailty, inflammatory status, and degree of platelet activation and reactivity in elderly subjects with type 2 diabetes or…
- Conditions
- Coronary Artery Disease, Diabetes Mellitus, Type 2, Alzheimer Disease
- Trial name
- PIPAF (NCT05798637)
- Testing
- Standard of care
- Where
- 2 sites in Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Perugia
Alzheimer's Type Dementia
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.
- Trial name
- NCT01404169
- Testing
- E2020
- Where
- 32 sites in China
- Volunteers
- 260 people
- Sponsor
- Eisai Limited
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Alzheimer's Disease
Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease
The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.
- Trial name
- NCT00130429
- Testing
- PYM50028
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Phytopharm
Dementia, Dementia Frontotemporal
Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions
The overall objective of this study is to compare knowledge, decisional conflict, preferences, and caregiver burden over time caregivers of Alzheimer's Disease and Related Dementias (ADRD) patients by comparing the effectiveness…
- Conditions
- Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild
- Trial name
- NCT05165186
- Testing
- Video Intervention Arm
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Dementia of the Alzheimer's Type
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).
- Trial name
- NCT02434666
- Testing
- CPC-201
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Alzheimer's Disease
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
Open-label treatment with MPC-7869 for participants in a previous randomized study.
- Trial name
- NCT00380276
- Testing
- MPC-7869
- Where
- 90 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Myrexis Inc.
Alzheimer's Disease
Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.
- Trial name
- NCT00857649
- Testing
- Memantine
- Where
- 23 sites in Canada
- Volunteers
- 369 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in…
- Trial name
- Sirocco (NCT00501111)
- Testing
- AZD3480, Donepezil
- Where
- 70 sites in Austria, Belgium and 8 more
- Volunteers
- 659 people
- Sponsor
- AstraZeneca
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.